Category Archives: Public Policy

Latest From Public Policy

CHI Offering Free Webinar on FDA Draft Guidances

chi-logo-btn

The California Healthcare Institute will be hosting a free online discussion on Tuesday, October 25, 2011 that addresses the FDA’s recently released draft guidance documents: Draft Guidance for Industry and Food and Drug Administration Staff – Factors to Consider when Making Benefit-Risk Determinations in Medical Device Premarket Review (Aug. 15, 2011) Draft Guidance for Industry, Clinical Investigators, and Food and Drug Administration Staff – Design Considerations for Pivotal Clinical Investigations for Medical Devices (Aug. 15, 2011) Date: October Read More >

Public Policy  |  2 Comments  |  Email This Post
Tags: , ,

Ten Years After 9/11 and the Anthrax Attacks

Bacillus anthracis

Yesterday, the U.S. Senate Committee on Homeland Security and Governmental Affairs held a hearing entitled, “Ten Years After 9/11 and the Anthrax Attacks: Protecting Against Biological Threats”. As stated by Chairman Lieberman in his opening remarks, the goal of the hearing was to examine whether the federal government “has developed the tools we need to respond effectively to a bioterror attack or naturally-occurring pandemic disease, to develop and disseminate vaccines and antibiotics, and to respond Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Boosting Investment in Biotech

Biofuel Research

The President’s Council on Jobs and Competitiveness issued an interim report with suggestions to increase job creation and growth in the U.S., as well as plans for encouraging investment in the industry. Of particular interest to the biotech industry, the report offers suggestions for streamlining the FDA approval process. The report also outlines ideas for eliminating capital gains on investments of $25 million or less that are held for at least five years and recommends Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Incentivizing Biotech Growth; States and Regions Look to Stand Out from the Crowd

map_sm_0_0

The United States’ prolonged economic woes have drastically impacted state budgets, causing across-the-board program cuts and reassessment of priorities. The bioscience industry was not immune to the crisis, but did begin to rebound much faster than many other industries. Because the biosciences remain a source of high-wage, high-skill jobs, almost every state in the country is actively engaged in building fundamental industry infrastructure. State-sponsored programs to encourage investment and help bioscience companies leverage existing resources Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

KORUS and BIO’s New Senior Vice President for International Affairs

Joseph Damond

Earlier this week, Joseph Damond joined BIO as Senior Vice President of International Affairs.  He brings extensive experience in international affairs, trade and economics, most recently serving as Vice President of International Government Relations at Pfizer, Inc.  He previously served as Deputy Vice President for International Affairs at PhRMA and as the Deputy Assistant for the Asia-Pacific region in the Office of the U.S. Trade Representative. Joe will spearhead BIO’s international trade policy and help Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,